ATE335515T1 - Morpholinobildgebung und therapie - Google Patents

Morpholinobildgebung und therapie

Info

Publication number
ATE335515T1
ATE335515T1 AT02731189T AT02731189T ATE335515T1 AT E335515 T1 ATE335515 T1 AT E335515T1 AT 02731189 T AT02731189 T AT 02731189T AT 02731189 T AT02731189 T AT 02731189T AT E335515 T1 ATE335515 T1 AT E335515T1
Authority
AT
Austria
Prior art keywords
target site
morpholino
agent
conjugate
mammal
Prior art date
Application number
AT02731189T
Other languages
English (en)
Inventor
Donald J Hnatowich
Mary Rusckowski
Guozheng Liu
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Application granted granted Critical
Publication of ATE335515T1 publication Critical patent/ATE335515T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicinal Preparation (AREA)
AT02731189T 2001-03-30 2002-04-01 Morpholinobildgebung und therapie ATE335515T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27980901P 2001-03-30 2001-03-30
US34179401P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
ATE335515T1 true ATE335515T1 (de) 2006-09-15

Family

ID=26959899

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731189T ATE335515T1 (de) 2001-03-30 2002-04-01 Morpholinobildgebung und therapie

Country Status (6)

Country Link
US (1) US6899864B2 (de)
EP (1) EP1372741B1 (de)
AT (1) ATE335515T1 (de)
AU (1) AU2002303181A1 (de)
DE (1) DE60213771T2 (de)
WO (1) WO2002078638A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
JP2006523706A (ja) * 2003-04-15 2006-10-19 イミューノメディクス、インコーポレイテッド 増幅ターゲッティングによるモルホリノイメージングおよび治療
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20070009435A1 (en) * 2005-07-06 2007-01-11 Syud Faisal A Compositions and methods for enhanced delivery to target sites
WO2008088865A2 (en) * 2007-01-19 2008-07-24 University Of Massachusetts Antisense and pretargeting optical imaging
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
IN2012DN03354A (de) 2009-12-02 2015-10-23 Immunomedics Inc
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
AU2014248886B2 (en) * 2013-03-12 2019-06-27 University Of Utah Research Foundation Compositions and methods for inducing apoptosis
US20140308205A1 (en) * 2013-04-12 2014-10-16 University Of Massachusetts Medical School Trifunctional and completely clearable specific targeting agents and methods thereof
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
EP3286224A4 (de) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
WO2018118759A1 (en) * 2016-12-19 2018-06-28 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927193A (en) * 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4468457A (en) * 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4479895A (en) * 1982-05-05 1984-10-30 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4460459A (en) * 1983-02-16 1984-07-17 Anschutz Mining Corporation Sequential flotation of sulfide ores
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4782840A (en) * 1984-03-02 1988-11-08 Neoprobe Corporation Method for locating, differentiating, and removing neoplasms
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
JP2528107B2 (ja) * 1985-03-15 1996-08-28 サマ−トン,ジエ−ムス ポリヌクレオチド測定試薬と方法
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
EP0637965B1 (de) 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
WO1993021940A1 (en) * 1992-05-06 1993-11-11 Immunomedics, Inc. Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
JPH11507046A (ja) * 1995-06-07 1999-06-22 イムノメディクス,インコーポレイテッド 診断剤および治療剤の標的部位への改良された送達方法

Also Published As

Publication number Publication date
DE60213771T2 (de) 2007-08-16
EP1372741B1 (de) 2006-08-09
DE60213771D1 (en) 2006-09-21
WO2002078638A2 (en) 2002-10-10
US20030003102A1 (en) 2003-01-02
AU2002303181A1 (en) 2002-10-15
US6899864B2 (en) 2005-05-31
EP1372741A4 (de) 2004-06-16
EP1372741A2 (de) 2004-01-02
WO2002078638A3 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
EP1372741A4 (de) Morpholinobildgebung und therapie
ATE365562T1 (de) Zielgerichtete kombinations-immuntherapie für krebs
DK0841949T3 (da) Anvendelse af saccharid-konjugater
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
EP1465666A4 (de) Aus mehreren komponenten bestehende anordnung mit verbesserten bindungseigenschaften zur diagnose und therapie
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
EP0837696A4 (de) Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
DK0627940T3 (da) Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
WO1999067284A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DK1594542T3 (da) Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
DK0907379T3 (da) Bioaktiveret diagnostisk billeddannelseskontrastmiddel
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
WO2001098294A3 (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
DE60045847D1 (de) Rezeptorbindende konjugate
DE60320398D1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
EP1532162A4 (de) Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties